BerandaDBVTF • OTCMKTS
add
DBV Technologies SA
Tutup sebelumnya
$0,79
Rentang tahun
$0,79 - $0,79
Kapitalisasi pasar
230,02Â jt USD
Volume Rata-Rata
33,33Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
EPA
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 753,00Â rb | -46,48% |
Biaya operasional | 27,37Â jt | -8,66% |
Laba bersih | -27,08Â jt | 0,97% |
Margin laba bersih | -3,60Â rb | -85,03% |
Penghasilan per saham | -0,23 | 91,18% |
EBITDA | -25,67Â jt | 9,96% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 12,96Â jt | -87,23% |
Total aset | 50,56Â jt | -65,34% |
Total liabilitas | 47,69Â jt | 39,27% |
Total ekuitas | 2,87 jt | — |
Saham yang beredar | 136,72 jt | — |
Harga terhadap nilai buku | 26,20 | — |
Tingkat pengembalian aset | -114,52% | — |
Tingkat pengembalian modal | -299,45% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -27,08Â jt | 0,97% |
Kas dari operasi | -19,67Â jt | 43,31% |
Kas dari investasi | -375,00Â rb | 82,41% |
Kas dari pembiayaan | 45,00Â rb | 172,58% |
Perubahan kas bersih | -19,49Â jt | 51,07% |
Arus kas bebas | -9,34Â jt | 66,16% |
Tentang
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
Didirikan
29 Mar 2002
Situs
Karyawan
106
